Search

Your search keyword '"Ramírez, Javier Sánchez"' showing total 11 results
Start Over Author "Ramírez, Javier Sánchez" Publication Year Range Last 50 years
11 results on '"Ramírez, Javier Sánchez"'

1. Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

Author

Gaynor, Nicola, primary, Blanco, Alfonso, additional, Madden, Stephen F., additional, Moran, Barry, additional, Fletcher, Jean M., additional, Kaukonen, Damien, additional, Ramírez, Javier Sánchez, additional, Eustace, Alex J., additional, McDermott, Martina S. J., additional, Canonici, Alexandra, additional, Toomey, Sinead, additional, Teiserskiene, Ausra, additional, Hennessy, Bryan T., additional, O’Donovan, Norma, additional, Crown, John, additional, and Collins, Denis M., additional

Published
2023
Full Text
View/download PDF

2. Additional file 2 of Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Author

Ramírez, Javier Sánchez, Yanelys Morera Díaz, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Yenima Martín Bauta, Katty-Hind Selman-Housein Bernal, Santos, Ana Victoria De La Torre, Iglesia, Mariela Pérez De La, Lorenzo, Lian Trimiño, and Avila, Marta Ayala

Abstract

Additional file 2. Reagents.

Published
2020
Full Text
View/download PDF

3. Additional file 3 of Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Author

Ramírez, Javier Sánchez, Yanelys Morera Díaz, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Yenima Martín Bauta, Katty-Hind Selman-Housein Bernal, Santos, Ana Victoria De La Torre, Iglesia, Mariela Pérez De La, Lorenzo, Lian Trimiño, and Avila, Marta Ayala

Subjects
genetic structures, sense organs, eye diseases
Abstract

Additional file 3. Biotinylation of bevacizumab did not affect the binding to VEGF.

Published
2020
Full Text
View/download PDF

4. Additional file 5 of Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Author

Ramírez, Javier Sánchez, Yanelys Morera Díaz, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Yenima Martín Bauta, Katty-Hind Selman-Housein Bernal, Santos, Ana Victoria De La Torre, Iglesia, Mariela Pérez De La, Lorenzo, Lian Trimiño, and Avila, Marta Ayala

Abstract

Additional file 5. Half maximal effective concentration (EC50) for biotinylated bevacizumab obtained from four independent experiments.

Published
2020
Full Text
View/download PDF

5. Additional file 4 of Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Author

Ramírez, Javier Sánchez, Yanelys Morera Díaz, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Yenima Martín Bauta, Katty-Hind Selman-Housein Bernal, Santos, Ana Victoria De La Torre, Iglesia, Mariela Pérez De La, Lorenzo, Lian Trimiño, and Avila, Marta Ayala

Subjects
endocrine system, animal structures, viruses, fungi, embryonic structures
Abstract

Additional file 4. Human VEGF-C from transfected CHO cells.

Published
2020
Full Text
View/download PDF

6. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.

Author

Ramírez, Javier Sánchez, primary, Díaz, Yanelys Morera, additional, Bequet-Romero, Mónica, additional, Hernández-Bernal, Francisco, additional, Bauta, Yenima Martín, additional, Bernal, Katty-Hind Selman-Housein, additional, Santos, Ana Victoria de la Torre, additional, Iglesia, Mariela Pérez de la, additional, Lorenzo, Lian Trimiño, additional, Program, Team of Investigators of Compassionate use, additional, and Avila, Marta Ayala, additional

Published
2020
Full Text
View/download PDF

7. Specific humoral response in cancer patients treated with a VEGF therapeutic vaccine under a compassionate use program

Author

Ramírez, Javier Sánchez, primary, Díaz, Yanelys Morera, additional, Bequet-Romero, Mónica, additional, Hernández-Bernal, Francisco, additional, Bauta, Yenima Martín, additional, Bernal, Katty-Hind Selman-Housein, additional, Santos, Ana Victoria de la Torre, additional, Iglesia, Mariela Pérez de la, additional, Lorenzo, Lian Trimiño, additional, Program, Team of Investigators of Compassionate use, additional, and Avila, Marta Ayala, additional

Published
2019
Full Text
View/download PDF

8. Additional file 3: of Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Author

Ramírez, Javier Sánchez, Yanelys Morera Díaz, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Katty-Hind Selman-Housein Bernal, Santos, Ana De La Torre, Álvarez, Eduardo Santiesteban, Yenima Martín Bauta, Cimara Bermúdez Badell, Pupo, Josué De La Torre, Gavilondo, Jorge, and Avila, Marta Ayala

Subjects
body regions, nervous system, fungi
Abstract

Detection of specific-IgG, IgM or IgA immunoglobulin classes at the end of trial vaccinations (week 13). (PDF 100 kb)

Published
2017
Full Text
View/download PDF

9. Additional file 5: of Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Author

Ramírez, Javier Sánchez, Yanelys Morera Díaz, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Katty-Hind Selman-Housein Bernal, Santos, Ana De La Torre, Álvarez, Eduardo Santiesteban, Yenima Martín Bauta, Cimara Bermúdez Badell, Pupo, Josué De La Torre, Gavilondo, Jorge, and Avila, Marta Ayala

Subjects
body regions, nervous system, fungi, bacteria, biochemical phenomena, metabolism, and nutrition
Abstract

Off-trial re-immunizations. (PDF 97 kb)

Published
2017
Full Text
View/download PDF

10. Additional file 1: of Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Author

Ramírez, Javier Sánchez, Yanelys Morera Díaz, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Katty-Hind Selman-Housein Bernal, Santos, Ana De La Torre, Álvarez, Eduardo Santiesteban, Yenima Martín Bauta, Cimara Bermúdez Badell, Pupo, Josué De La Torre, Gavilondo, Jorge, and Avila, Marta Ayala

Subjects
body regions, nervous system, fungi
Abstract

Reported adverse events which were probably or definitively related to the vaccine during trial period. (PDF 113 kb)

Published
2017
Full Text
View/download PDF

11. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.

Author

Ramírez, Javier Sánchez, Díaz, Yanelys Morera, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Bernal, Katty-Hind Selman-Housein, de la Torre Santos, Ana, Álvarez, Eduardo Rafael Santiesteban, Bauta, Yenima Martín, Badell, Cimara H. Bermúdez, de la Torre Pupo, Josué, and Gavilondo, Jorge V.

Subjects
*TUMORS, *HUMORAL immunity, *IMMUNOTHERAPY, *TUMOR treatment, *VASCULAR endothelial growth factor receptors, *BIOAVAILABILITY, *PATIENTS
Abstract

Background: CIGB-247, a VSSP-adjuvanted VEGF-based vaccine, was evaluated in a phase I clinical trial in patients with advanced solid tumors (CENTAURO). Vaccination with the maximum dose of antigen showed an excellent safety profile, exhibited the highest immunogenicity and was the only one showing a reduction on platelet VEGF bioavailability. However, this antigen dose level did not achieve a complete seroconversion rate in vaccinated patients. These clinical results led us to the question whether a "reserve" of untapped immune response potential against VEGF could exist in cancer patients. To address this matter, CENTAURO-2 clinical trial was conducted where antigen and VSSP dose scale up were studied, and also incorporated the exploration of aluminum phosphate as adjuvant. These changes were made with the aim to increase immune response against VEGF. Results: The present study reports the characterization of the humoral response elicited by CIGB-247 from the combining of different antigen doses and adjuvants. Cancer patients were immunologically monitored for approximately 1 year. Vaccination with different CIGB-247 formulations exhibited a very positive safety profile. Cancer patients developed IgM, IgG or IgA antibodies specific to VEGF. Elicited polyclonal antibodies had the ability to block the interaction between VEGF and its receptors, VEGFR1 and VEGFR2. The highest humoral response was detected in patients immunized with 800 μg of antigen + 200 µg of VSSP. Off-protocol long-term vaccination did not produce negative changes in humoral response. Conclusions: Vaccination with a human VEGF variant molecule as antigen in combination with VSSP or aluminum phosphate is immunogenic. The results of this study could contribute to the investigation of this vaccine therapy in an adequately powered efficacy trial. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results